FDA authorizes Allergan’s oral medication Ubrelvy to treat migraine
Category: #health  By Pankaj Singh  Date: 2019-12-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA authorizes Allergan’s oral medication Ubrelvy to treat migraine

FDA authorizes Allergan’s oral medication Ubrelvy to treat migraine

Allergan, a renowned Irish pharmaceutical company involved in acquisition, development and marketing of brand-name medications, reportedly announced the FDA approval for Ubrelvy, a novel drug innovated to treat migraines.   

This new series of drugs are known as CGRP medications since they aim at the protein calcitonin gene-related peptide as well as its receptor. CGRP medications provide hope to migraine patients, who until recently only had a handful of treatment options. This is only the fourth novel CGRP medication to hit the medical market in the past two years. Also, this is the first medication that is in the form of a pill and not an injection.

Chief Commercial Officer of Allergan, Bill Meury stated that the company is very delighted with the outcomes. In clinical studies, Ubrelvy alleviated migraine-related pain for a significant portion of migraine patients, typically within two hours of consuming.

Meury further added that he wasn’t worried regarding the competition. He certainly didn’t see this as a market share battle. When suffering from disease as common as migraines, having more options is better.

A fifth CGRP is predicted to hit the market soon. Biohaven Pharmaceuticals expects authorization for its CGRP medication, called Rimegepant. The medication may be out during the first quarter of 2020 stated Vlad Coric, CEO at Biohaven Pharmaceuticals.

Coric further added that for Biohaven, which was founded comparatively recently in 2013, Rimegepant would be its first approved drug. Unlike the Allergan medication, Biohaven is also providing its drug in a nasal spray form. This kind of nasal spray is important for migraine sufferers who witness nausea and might not be capable of taking pills.  

It was a proud moment for migraine therapy when the first three CGRP migraine drugs launched in the market in 2018. Those medications are Emgality, from Eli Lilly, Teva’s Ajovy, and Aimovig from Novartis and Amgen. These medications were created specifically to treat migraines in approximately 25 years. Also, these were the first medications ever that were approved particularly to prevent migraines. Approximately one out of seven Americans are affected by migraine.

 

Source credit: https://www.forbes.com/sites/leahrosenbaum/2019/12/24/with-new-fda-approval-the-migraine-medication-revolution-continues/#783a72b26ab5



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...